Omeprazole Inhibits Phagocytosis and Acidification of Phagolysosomes of Normal Human Neutrophils In Vitro

References

• Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjosstrand S. E., Wallmark B. Substituted benzimidazoles block gastric acid secretion by blocking H+-K+ ATPase. Nature 1981; 290: 159–61
   PubMed Web of Science ®Google Scholar
• Styrt B., Klempner M. S. Internal pH of human neutrophil lysosomes. F.E.B.S. Lett. 1982; 149: 113–6
   PubMedGoogle Scholar
• Mollenedo F., Manara F. S., Schneider D. L. Acidification activity of human neutrophils. Tertiary granules as a site of ATP dependent acidification. J. Biol. Chem. 1986; 261(3)1077–82
   Google Scholar
• Wandell J. H. Effects of omeprazole on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Gut 1992; 33: 617–21
   PubMedGoogle Scholar
• West B. C., Rosenthal A. S., Gelb N. A., Kimball H. R. Separation and characterization of human neutrophil granules. Am. J. Pathol. 1974; 77(1)41–62
   PubMedGoogle Scholar
• Glantz S. A. Primer of biostatistics, 3rd ed. McGraw-Hill, Inc., New York, NY 1992; 93–94; 100–101
   Google Scholar
• Mandell G. L. Intraphagolysosomal pH of human polymorphonuclear neutrophils. Proc. Soc. Exp. Biol. Med. 1970; 134: 447–9
   PubMed Web of Science ®Google Scholar
• Dubos R. J. Biochemical determinants of microbial diseases. Harvard University Press, Cambridge, MA 1954; 12
   Google Scholar
• Klempner M. S., Styrt B. Alkalinizing the intralysosomal pH inhibits degranulation of human neutrophils and monocytes. J. Clin. Invest. 1983; 72: 1793–1800
   PubMedGoogle Scholar
• Jacques Y. V., Bainton D. F. Changes in pH within the phagocytic vacuoles of human neutrophils and monocytes. Lab. Invest. 1978; 39(3)179–85
   PubMedGoogle Scholar
• Barrett A. J. Lysosomes in biology and pathology, J. T. Dingle, H. B. Fell. North Holland Publishing Co., Amsterdam 1969; Vol. 2: 244
   Google Scholar
• Wallmark B., Brandstrom H., Larsson H. Evidence for acid-induced transformation of omeprazole into an active inhibitor of H+-K+ ATPase inhibitor. Biochem. Biophys. Acta. 1984; 778: 549–58
   PubMedGoogle Scholar
• Shamburek R. D., Ruddy S., Schubert M. L. Omeprazole and neutrophil function. Gastroenterol. 1993; 104: 938–40
   PubMedGoogle Scholar
• Capodicasa E., Ciaccio V., Corazzi F., De Bellis F., Bucaneve G., Ficola F., Pelli M. A. Reduced ex vivo production of superoxide anion by polymorphonuclear leukocytes during therapy with omeprazole. A pharmacological effect. Minerva Gastroenterol. Dietol. 1994; 40: 105–11
   PubMedGoogle Scholar
• Suzuki M., Mori M., Miura S., Suematsi M., Fukumara D., Kimura H., Ishii H. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radical Biol. Med. 1996; 21(5)727–731
   PubMedGoogle Scholar
• Suzuki M., Nakamura M., Miura S., Mori M., Tsuchiya M., Ishii H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J. Clin. Gastroenterol. 1995; 20: S93–S96, (Suppl. 2)
   PubMedGoogle Scholar
• Neal K. R., Scott H. M., Slack R. C.B., Logan R. F.A. Omeprazole as a risk factor for Campylobacter gastroenteritis: case controlled study. B.M.J. 1996; 312: 414–5
   PubMed Web of Science ®Google Scholar
• Larner A. J., Lendrum R. Oesophageal candidiasis after omeprazole therapy. Gut 1992; 33(6)860–1
   PubMedGoogle Scholar
• Sood A., Sharma M., Jain N. P., Chawla L. S., Kumar R. Esophageal candidiasis following omeprazole therapy: a report of two cases. Ind. J. Gastroenterol. 1995; 14: 71–2
   PubMedGoogle Scholar
• Goenka M. K., Kochhar R., Chakrabarti A., Kumar A., Gupta O., Talwar P., Mehta S. K. Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. J. Clin. Gastroenterol. 1996; 23: 7–10
   PubMedGoogle Scholar
• Reynaert H., Fernandes E., Bourgain C., Smekens L., Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association. J. Gastroenterol. 1995; 30: 775–8
   PubMed Web of Science ®Google Scholar
• Fakir M., Saison C., Wong T., Matta B., Hardin J-M. Septicemia due to Yersinia enterocolitica in a hemodialyzed, iron-depleted patient receiving omeprazole and oral iron supplementation. Am. J. Kid. Dis. 1992; 19: 282–4
   PubMedGoogle Scholar
• Wingate D. L. Acid reduction and recurrent enteritis. Lancet 1990; 335: 222
   PubMed Web of Science ®Google Scholar
• Littman A. Potent acid reduction and risk of enteric infection. Lancet 1990; 335: 222
   PubMedGoogle Scholar
• Rantala A., Ovasaka J. Association between medically induced achlorhydria of the stomach and a severe postoperative infection? A report of two cases. Ann. Chir. Gynaecol. 1994; 83: 268–70
   PubMedGoogle Scholar
• West B. C., Agastya G., Sodeman W., Callahan J. Furunculosis associated with repeated courses of omeprazole therapy. Clin. Inf. Dis. 1998; 26: 1234–5
   PubMedGoogle Scholar
• Suzuki M., Mori M., Miyayama A., Iwai N., Tsunematsu N., Oonuki M., Suzuki H., Hibi T., Ishii H. Enhancement of neutrophil infiltration into the corpus after failure of Helicobacter pylori eradication. J. Clin. Gastroenterol. 1997; 25: S222–S228, (Suppl. 1)
   PubMedGoogle Scholar
• Tsunoda T., Tanimura H., Yamaue H., Iwahashi M., Tani M., Tamai M., Arii K., Noguchi K. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor infiltrating lymphocytes by famotidine in cancer patients. Int. J. Immunopharmacol. 1992; 14(1)75–81
   PubMedGoogle Scholar
• Aybay C., Imir T., Okur H. The effect of omeprazole on human natural killer cell activity. Gen. Pharmacol. 1995; 26(6)1413–8
   PubMedGoogle Scholar
• Holm L. Gastric mucosal blood flow and mucosal protection. J. Clin. Gastroenterol. 1988; 10: S114–S9, (suppl. 1)
   PubMedGoogle Scholar
• McGowan C. C., Cover T. L., Blaser M. J. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease independent mechanism. Gastroenterol. 1994; 107: 1573–8
   PubMedGoogle Scholar
• Prilosec Anonymous. (omeprazole) package insert. Astra Merk, Inc., Wayne, PA 1995
   Google Scholar
• Vinayek R., Anantea M. A., Maton P. A., Frucht H., Gardner J. D., Jensen R. T. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterol. 1991; 101: 138–47
   PubMed Web of Science ®Google Scholar
• Cederberg C., Thomas A. B., Mahachai V., Westin J. A., Kerdeski P., Fisher D., Zuk L., Marriage B. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterol. 1992; 913–8
   PubMedGoogle Scholar